BerGenBio AS (“BerGenBio” or the “Company”), an oncology biopharmaceutical company, today announces that the first patient has been dosed in its multi-centre Phase 1b trial (BGBC003) of BGB324, a selective inhibitor of Axl, in patients with acute myeloid leukaemia (AML) at Haukeland University Hospital in Bergen, Norway.

Press release